Premium
Within‐clinic Glycosylated Haemoglobin Measurement
Author(s) -
Rumley Mr.A.G.,
Carlton G.,
Small M.
Publication year - 1990
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1990.tb01502.x
Subject(s) - medicine , diabetes mellitus , insulin , glycosylated haemoglobin , analyser , glycated haemoglobin , diabetes management , endocrinology , type 2 diabetes , chromatography , chemistry
The performance of the Diamat HPLC analyser (Bio Rad Instruments) was assessed, and the effect of this on‐site HbA 1 assay on the therapeutic decisions made at the diabetic clinic evaluated. The intra‐assay CV for HbA 1 at concentrations of 8.3 and 13.4 % was 3.8 and 0.4 %, respectively, with inter‐assay CV of 5.0 and 3.0 %. On a single day 82 HbA 1 tests on consecutive patients were performed at the clinic. In 43 insulin‐treated patients and 79 non‐insulin‐treated diabetic patients the HbA 1 result changed the management decision in 25 and 18 % of patients, respectively. The relationship between HbA 1 and self blood glucose monitoring (SBGM) results in the previous 6‐week period were also evaluated. In 41 % of patients with insulin‐treated diabetes who produced SBGM diaries there was a discrepancy between categories of blood glucose control, all of these patients having better SBGM than HbA 1 values. This study highlights the feasibility and value of a within‐clinic HbA 1 assay for clinical decision‐making and its usefulness in identifying problems of agreement with self‐monitored tests.